Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, Europe, Latin America, the Asia Pacific, and Africa. The company operates in Pharmaceuticals and Consumer Products segments. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; and products in the therapeutic areas of pain management, neurology, dermatology, liver diseases, and other areas. The company also provides consumer wellness products, such as Complan; EverYuth, a range of skincare products; Nycil; Glucon-D glucose powder; Nutralite; Nutralite Doodhshakti, a portfolio of dairy products; and various other products. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, ophthalmology, inflammation, rheumatology, hepatology, infectious disease, etc. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is based in Ahmedabad, India.
Zydus Lifesciences Dividend Announcement
• Zydus Lifesciences announced a annually dividend of ₹3.00 per ordinary share which will be made payable on 2024-09-08. Ex dividend date: 2024-07-26
• Zydus Lifesciences annual dividend for 2024 was ₹3.00
• Zydus Lifesciences annual dividend for 2023 was ₹6.00
• Zydus Lifesciences's trailing twelve-month (TTM) dividend yield is 0.31%
• Zydus Lifesciences's dividend growth over the last five years (2018-2023) was 11.38% year
• Zydus Lifesciences's dividend growth over the last ten years (2013-2023) was -2.21% year
Zydus Lifesciences Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2024-07-26 | ₹3.00 | annually | 2024-09-08 |
2023-07-27 | ₹6.00 | annually | 2023-09-10 |
2022-07-28 | ₹2.50 | annually | 2022-08-16 |
2021-07-28 | ₹3.50 | annually | 2021-09-10 |
2020-03-23 | ₹3.50 | annually | 2020-04-15 |
2019-07-25 | ₹3.50 | annually | 2019-09-08 |
2018-07-31 | ₹3.50 | annually | 2018-09-12 |
2017-03-16 | ₹3.20 | annually | 2017-04-06 |
2016-03-17 | ₹3.20 | annually | |
2015-07-30 | ₹12.00 | annually | |
2014-07-17 | ₹9.00 | annually | |
2013-06-11 | ₹7.50 | annually |
Zydus Lifesciences Dividend per year
Zydus Lifesciences Dividend growth
Zydus Lifesciences Dividend Yield
Zydus Lifesciences current trailing twelve-month (TTM) dividend yield is 0.31%. Interested in purchasing Zydus Lifesciences stock? Use our calculator to estimate your expected dividend yield:
Zydus Lifesciences Financial Ratios
Zydus Lifesciences Dividend FAQ
Other factors to consider when evaluating Zydus Lifesciences as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Zydus Lifesciences stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Zydus Lifesciences's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Zydus Lifesciences publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Zydus Lifesciences distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Zydus Lifesciences are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Zydus Lifesciences sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Zydus Lifesciences distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Zydus Lifesciences declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Zydus Lifesciences's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Zydus Lifesciences's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.